DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Summary for Patent: 8,454,996
|Title:||Pharmaceutical composition for the treatment of acute disorders|
|Abstract:||A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.|
|Inventor(s):||Pettersson; Anders (Kode, SE), Nystrom; Christer (Lidingo, SE)|
|Assignee:||Orexo AB (Uppsala, SE)|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for patent 8,454,996|
1. A method comprising sublingual administration to an individual of a pharmaceutical composition in the form of a tablet sized for placement under a tongue, wherein the composition
comprises (a) water-soluble carrier particles having exterior surfaces, (b) microparticles of buprenorphine or a pharmaceutically-acceptable salt thereof, wherein said microparticles are smaller than the carrier particles and are admixed with the carrier
particles, and (c) particles of a bioadhesion and/or mucoadhesion promoting agent consisting essentially of a polymer that swells when brought into contact with saliva, admixed with the carrier particles, wherein the microparticles of buprenorphine or a
pharmaceutically-acceptable salt thereof are presented at the exterior surfaces of the carrier particles.
2. A method comprising sublingual administration of at least one dosage unit of an essentially water free pharmaceutical composition to an individual, said pharmaceutical composition comprising an effective amount of buprenorphine or a pharmaceutically-acceptable salt thereof in the form of microparticles adhered to the surfaces of carrier particles which are substantially larger than said microparticles and are essentially water-soluble, and a bioadhesion and/or mucoadhesion promoting agent.
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.